Regenerx Biopharmaceuticals Reports Converting Non-Beating Heart Cells ($RGRX)

RegeneRx (OTCBB: RGRX) is a clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

Regenerx, in conjunction with Gladstone Institute of Cardiovascular Disease, has published new animal data demonstrating Thymosin beta 4 when used with GMT gene therapy enhanced the conversion of non-beating heart cells into functional, beating heart muscle cells after heart attack.  Data published in the current issue of Nature shows that these experiments were successful in reducing scar tissue and improving heart function when compared to GMT or Tβ4 alone. 

Dr. Deepak Srivastava, a Regenerx scientific advisory board member, commented,

“Our experiments in mice are a proof of concept that we can reprogram non-beating cells directly into fully functional, beating heart cells – offering an innovative and less invasive way to restore heart function after a heart attack.”

Read the full article here.